Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. | Zendy

A. Horwich | Zendy; D.Th. Sleijfer | Zendy; Sophie D. Fosså | Zendy; Stan B. Kaye | Zendy; R.T.D. Oliver | Zendy; M.H. Cullen | Zendy; Graham M. Mead | Zendy; Ronald de Wit | Zendy; P H de Mulder | Zendy; D.P. Dearnaley | Zendy; Pat Cook | Zendy; R. J. Sylvester | Zendy; SP Stenning | Zendy

Open Access

Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.

Author(s) -

A. Horwich,

D.Th. Sleijfer,

Sophie D. Fosså,

Stan B. Kaye,

R.T.D. Oliver,

M.H. Cullen,

Graham M. Mead,

Ronald de Wit,

P H de Mulder,

D.P. Dearnaley,

Pat Cook,

R. J. Sylvester,

SP Stenning

Publication year - 1997

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.1997.15.5.1844

Subject(s) - medicine , etoposide , carboplatin , bleomycin , germ cell tumors , chemotherapy , randomized controlled trial , cisplatin , urology , oncology , surgery

This prospective randomized multicenter trial was designed to evaluate the efficacy of carboplatin plus etoposide and bleomycin (CEB) versus cisplatin plus etoposide and bleomycin (BEP) in first-line chemotherapy of patients with good-risk nonseminomatous germ cell tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research